Focused On-demand Library for Serine/threonine-protein kinase TAO1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q7L7X3

UPID:

TAOK1_HUMAN

Alternative names:

Kinase from chicken homolog B; MARK Kinase; Prostate-derived sterile 20-like kinase 2; Thousand and one amino acid protein kinase 1

Alternative UPACC:

Q7L7X3; A2RUT8; B7ZLV6; Q96L75; Q9H2K7; Q9H7S5; Q9P2I6

Background:

Serine/threonine-protein kinase TAO1, also known as Kinase from chicken homolog B, MARK Kinase, Prostate-derived sterile 20-like kinase 2, and Thousand and one amino acid protein kinase 1, plays a pivotal role in various cellular processes. These include the p38/MAPK14 stress-activated MAPK cascade, DNA damage response, regulation of cytoskeleton stability, G-protein coupled receptor signaling, and apoptosis. It is essential for neuronal development in the central nervous system.

Therapeutic significance:

The involvement of Serine/threonine-protein kinase TAO1 in developmental delay with or without intellectual impairment or behavioral abnormalities highlights its potential as a target for therapeutic intervention. Understanding the role of Serine/threonine-protein kinase TAO1 could open doors to potential therapeutic strategies.